on a valuation basis you are right that regn is overvalued. the problem is that large biotech and pharma have been paying sky high valuations for early stage projects and regn already has a good deal with sanofi on the vegf trap and they might just buy them out
a short into the scenario would cause you a lot of pain
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.